A	B	C
1	Main
2		Brand	Syfovre
3		Indication	Geographic atrophy
4		Administraiton	intravitreal qm or q2m
5		Regulatory	EU, Canada, Australia, UK, Switzerland decisions expected 1H2024
6
7			Phase III "DERBY" n=621 GA-AMD
8			Reduced extrafoveal GA growth by 17% with monthly and 23% q2m.
9			5.6 letters better than sham in extrafoveal lesions
10
11			Phase III "OAKS" n=637 GA-AMD
12			Reduced extrafoveal GA growth by 33% with monthly and 17% q2m.
13
14			Phase II "FILLY" n=246 GA-AMD